Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations.

Haowei Wang,Lei Cheng,Chao Zhao,Fei Zhou,Tao Jiang,Haoyue Guo,Jinpeng Shi,Peixin Chen,Zhuoran Tang,Shiqi Mao,Keyi Jia,Lingyun Ye,Chenlei Cai,Xuefei Li,Xiaoxia Chen,Caicun Zhou

Translational lung cancer research（2023）

引用 1|浏览28

暂无评分

摘要

The findings observed an evidential and significant susceptibility to ICIs combined therapy in patients with -mutant NSCLC, especially in first-line treatment.

查看译文

关键词

BRAF-mutant,immune checkpoint inhibitors (ICI),non-small cell lung cancer (NSCLC),progression-free survival (PFS)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要